What is the long-term trend for Corcept Therapeutics's cash received from option exercises?

Over 2 years (2023 to 2025), Corcept Therapeutics's cash received from option exercises has grown at a 183.3% compound annual growth rate (CAGR), from $1.98M to $15.87M.

Corcept Therapeutics CORT Cash received from option exercises

Cash received from option exercises at other companies

Coeur MiningCDE

$3.35M+13,300%

AeroVironmentAVAV

$460.25K—

Vertex PharmaceuticalsVRTX

$13.9M+11.2%

WelltowerWELL

$332K-71.9%

Ford Motor CompanyF

$750K—

Flutter EntertainmentFLUT

$4M+33.3%

Other financials

Income statement

See full

Revenue$164.9M+4.9%

Gross profit$162.0M+4.7%

Operating income-$49.6M-1,552%

Net income-$31.8M-255%

EPS (diluted)-$0.30-276%

Balance sheet

See full

Cash & equivalents$110.0M+21.1%

Total debt$9.6M+41.0%

Total equity$638.0M-6.6%

Total assets$814.9M-3.7%

Cash flow

See full

Operating cash flow-$16.8M-452%

CapEx$201.0K+93.3%

Free cash flow-$17.0M-464%

Valuation

See full

Market cap$8.58B-64.4%

Enterprise value$8.48B-65.0%

P/E181.2×+1.3×

P/S11.2×-24.0×

Profitability

See full

Gross margin98.3%-0.2pp

Operating margin-1.1%-17.2pp

Net margin6.2%-13.4pp

FCF margin15.6%-10.2pp

Returns & leverage

See full

Return on equity7.2%-14.6pp

Debt / equity0×0.0×

Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corcept Therapeutics's cash received from option exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Corcept Therapeutics's cash received from option exercises?: Corcept Therapeutics (CORT) reported cash received from option exercises of $3.98M in Q1 2026.
How has Corcept Therapeutics's cash received from option exercises changed year-over-year?: Corcept Therapeutics's cash received from option exercises increased by 129.0% year-over-year, from $1.74M to $3.98M.
What is the long-term trend for Corcept Therapeutics's cash received from option exercises?: Over 2 years (2023 to 2025), Corcept Therapeutics's cash received from option exercises has grown at a 183.3% compound annual growth rate (CAGR), from $1.98M to $15.87M.